7 News & Press Releases found
Aerami Therapeutics Holdings, Inc. News
-
Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium
Aerami Therapeutics, Inc. (the “Company”) announced today that Anne Whitaker, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 ...
-
Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use for patients. PAH is a rare and progressive ...
-
Aerami Therapeutics Appoints Lisa Yanez as Chief Executive Officer
Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa ...
-
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective ...
-
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing Plans to enter Phase 2/3 Trials ...
-
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing with results expected later this ...
-
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aeramiās PAH (pulmonary arterial hypertension) Drug Device Combination in China
Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases today announces the signing of an exclusive ...